Transforming the treatment of
Developer of first-in-class therapeutics targeting the IL-11 pathway
IL-11 signalling is a fundamentally important driver of fibrogenesis, organ dysfunction and inflammation across human fibrotic diseases.
Enleofen develops innovative, safe and highly effective therapeutics that address today’s biggest healthcare challenges.
Enx108A is a first-in-class human antibody that targets IL-11. Treatment with ENx108A is anti-fibrotic, anti-inflammatory and reverses organ dysfunction across disease models.